Live Breaking News & Updates on Oncologic Diseases|Page 2

Stay updated with breaking news from Oncologic diseases. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

NCCN Adds Nirogacestat to Guidelines for Patients With Soft Tissue Sarcoma

The NCCN has updated their guidelines for soft tissue sarcoma to include the γ-secretase inhibitor nirogacestat as a systemic therapy option for patients with desmoid tumors, granting the agent a preferred, category 1 recommendation.
....

United States , Richard Pazdur , Office Of Oncologic Diseases , National Comprehensive Cancer Network , Oncology Center , Oncologic Diseases , Drug Evaluation , Practice Guidelines , National Comprehensive Cancer Network , Soft Tissue Sarcoma Guidelines , Version 3 2023 , Ategory 1 Recommendation , Phase 3 Defi Trial Nct03785964 ,

FDA Approves Nirogacestat for Treatment of Desmoid Tumors

Desmoid tumors are noncancerous growths that appear in connective tissue, most often on the arms, legs, and abdomen. Aggressive tumors must be treated with surgery, radiation, or chemotherapy to keep them from growing into nearby organs, which can make them life-threatening. They can cause pain and disfigurement, and they can reduce functioning and quality of life. ....

United States , Saqib Islam , Richard Pazdur , Oncology Center , Office Of Oncologic Diseases , Springworks Therapeutics , Oncologic Diseases , Drug Evaluation , Mayo Clinic , New England Journal ,

FDA Approves Nirogacestat Tablets for Rare Desmoid Tumors

The approval is the first for a systemic therapy to treat desmoid tumors, offering patients an alternative to surgery. ....

United States , Springworks Thereapeutics , Richard Pazdur , Office Of Oncologic Diseases , Us Food Drug Administration , Oncology Center , Drug Administration , Springworks Therapeutics , Oncologic Diseases , Drug Evaluation , First Therapy , Rare Type , Secretase Inhibitor , Only Treatment , Desmoid Tumors , Non Cancer ,

FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

The FDA approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Nirogacestat is a new molecular entity and the first drug to be approved for the treatment of patients with desmoid tumors, a subtype of soft tissue sarcomas. ....

United States , Richard Pazdur , Drug Administration , Office Of Oncologic Diseases , Ogsiveo To Springworks Therapeutics Inc , Us Department Of Health , Human Services , Oncology Center , For Immediate Release , Oncologic Diseases , Drug Evaluation , Priority Review , Breakthrough Therapy , Springworks Therapeutics ,

First pill for desmoid tumours approved

First pill for desmoid tumours approved
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Saqib Islam , Richard Pazdur , Jeppe Gustafsson Shutterstock , Office Of Oncologic Diseases , Oncology Center , European Medicines Agency , Drug Administration , Jeppe Gustafsson , Springworks Therapeutic Ogsiveo , Oncologic Diseases , Drug Evaluation , New England Journal , Chief Executive Officer , Springworks Therapeutics , Works Therapeutics , Marketing Authorisation Application ,